Office-Based Opioid Treatment (OBOT) Certification
Office-Based Opioid Treatment (OBOT) removes barriers to medication-assisted treatment (MAT) for pregnant women. OBOT programs have proven to be effective, confidential, accessible and safe when used with engaged and motivated pregnant women. OBOT allows qualified practitioners with a Drug Addiction Treatment Act of 2000 (DATA) waiver to dispense or prescribe buprenorphine. Qualified providers include physicians, nurse practitioners (NPs), physician assistants (PAs), clinical nurse specialists (CNSs), certified registered nurse anesthetist (CRNAs), and certified nurse-midwives (CNMs).
Buprenorphine can be prescribed as a take-home prescription or administered on site. Referrals should still be made to wrap around substance use disorder counseling and other behavioral health services. Pregnant women who are candidates for buprenorphine treatment, should be inducted and maintained on the buprenorphine monoproduct. The efficacy of buprenorphine/naloxone combination product is unknown.
Office Based Opioid Therapy (OBOT): ASAM/ACOG certification for OB’s interested in providing office-based opioid therapy (OBOT). This course, with an OB/GYN focus, covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. The curriculum for this course has been specifically designed for women’s healthcare providers and is offered in collaboration with ACOG.
Reference: Kraus, M. L., Alford, D. P., Kotz, M. M., Levounis, P., Mandel, T. W., Meyer, M., … Wyatt, S. A. (2011, December). Statement of the American Society of Addiction Medicine Consensus Panel on the use of buprenorphine in office-based treatment of opioid addiction. Journal of Addiction Medicine, 5(4), 254–263.